Literature DB >> 16676322

Characterization of melanocyte-specific inducible Cre recombinase transgenic mice.

Marcus Bosenberg1, Viswanathan Muthusamy, David P Curley, Zhenxiong Wang, Cara Hobbs, Betsy Nelson, Cristina Nogueira, James W Horner, Ronald Depinho, Lynda Chin.   

Abstract

Conditional Cre-mediated recombination has emerged as a robust method of introducing somatic genetic alterations in an organ-specific manner in the mouse. Here, we generated and characterized mice harboring a 4-hydroxytamoxifen (OHT)-inducible Cre recombinase-estrogen receptor fusion transgene under the control of the melanocyte-specific tyrosinase promoter, designated Tyr::CreER(T2). Cre-mediated recombination was induced in melanocytes in a spatially and temporally controlled manner upon administration of OHT and was documented in embryonic melanoblasts, follicular bulb melanocytes, dermal dendritic melanocytes, epidermal melanocytes of tail skin, and in putative melanocyte stem cells located within the follicular bulge. Functional evidence suggestive of recombination in follicular melanocyte stem cells included the presence of Cre-mediated recombination in follicular bulb melanocytes 1 year after topical OHT administration, by which time several hair cycles have elapsed and the melanocytes residing in this location have undergone multiple rounds of apoptosis and replenishment. These Tyr:: CreER(T2) transgenic mice represent a useful resource for the evaluation of melanocyte developmental genetics, the characterization of melanocyte stem cell function and dynamics, and the construction of refined mouse models of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16676322     DOI: 10.1002/dvg.20205

Source DB:  PubMed          Journal:  Genesis        ISSN: 1526-954X            Impact factor:   2.487


  78 in total

1.  LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.

Authors:  Wenjin Liu; Kimberly B Monahan; Adam D Pfefferle; Takeshi Shimamura; Jessica Sorrentino; Keefe T Chan; David W Roadcap; David W Ollila; Nancy E Thomas; Diego H Castrillon; C Ryan Miller; Charles M Perou; Kwok-Kin Wong; James E Bear; Norman E Sharpless
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

2.  Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.

Authors:  Olga Shakhova; Daniel Zingg; Simon M Schaefer; Lisette Hari; Gianluca Civenni; Jacqueline Blunschi; Stéphanie Claudinot; Michal Okoniewski; Friedrich Beermann; Daniela Mihic-Probst; Holger Moch; Michael Wegner; Reinhard Dummer; Yann Barrandon; Paolo Cinelli; Lukas Sommer
Journal:  Nat Cell Biol       Date:  2012-07-08       Impact factor: 28.824

3.  In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma.

Authors:  Florian A Karreth; Yvonne Tay; Daniele Perna; Ugo Ala; Shen Mynn Tan; Alistair G Rust; Gina DeNicola; Kaitlyn A Webster; Dror Weiss; Pedro A Perez-Mancera; Michael Krauthammer; Ruth Halaban; Paolo Provero; David J Adams; David A Tuveson; Pier Paolo Pandolfi
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

4.  Melanocyte transformation requires complete loss of all pocket protein function via a mechanism that mitigates the need for MAPK pathway activation.

Authors:  I D Tonks; P Mukhopadhyay; W A Schroder; A Sorolla; A W Mould; H Y Handoko; B Ferguson; H K Muller; P Keith; N K Hayward; G J Walker; G F Kay
Journal:  Oncogene       Date:  2017-02-13       Impact factor: 9.867

5.  Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.

Authors:  Victoria Marsh Durban; Marian M Deuker; Marcus W Bosenberg; Wayne Phillips; Martin McMahon
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

6.  Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma.

Authors:  Michael B Mann; Michael A Black; Devin J Jones; Jerrold M Ward; Christopher Chin Kuan Yew; Justin Y Newberg; Adam J Dupuy; Alistair G Rust; Marcus W Bosenberg; Martin McMahon; Cristin G Print; Neal G Copeland; Nancy A Jenkins
Journal:  Nat Genet       Date:  2015-04-13       Impact factor: 38.330

7.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

8.  Mammalian pigmentation is regulated by a distinct cAMP-dependent mechanism that controls melanosome pH.

Authors:  Dalee Zhou; Koji Ota; Charlee Nardin; Michelle Feldman; Adam Widman; Olivia Wind; Amanda Simon; Michael Reilly; Lonny R Levin; Jochen Buck; Kazumasa Wakamatsu; Shosuke Ito; Jonathan H Zippin
Journal:  Sci Signal       Date:  2018-11-06       Impact factor: 8.192

9.  PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.

Authors:  Kristen S Hill; Evan R Roberts; Xue Wang; Ellen Marin; Taeeun D Park; Sorany Son; Yuan Ren; Bin Fang; Sean Yoder; Sungjune Kim; Lixin Wan; Amod A Sarnaik; John M Koomen; Jane L Messina; Jamie K Teer; Youngchul Kim; Jie Wu; Charles E Chalfant; Minjung Kim
Journal:  Mol Cancer Res       Date:  2018-10-24       Impact factor: 5.852

10.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.